NFE2L2 and hepatocellular carcinoma: In one such study, pharmacological inhibition of nuclear factor erythroid 2-related factor 2 (NRF2; a protein that affords protection against ferroptosis owing to its role in GSH synthesis) effectively ameliorated the resistance of hepatocellular carcinoma cells to ferroptosis induced by either erastin or sorafenib [66].